Lv6
2940 积分 2023-11-20 加入
Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody–drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials
3天前
已完结
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
3天前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
3天前
已完结
The promise of bispecific antibodies: Clinical applications and challenges
4天前
已完结
Clinical strategies for lymphoma management: Recommendations from the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Consensus Conference 2025
5天前
已完结
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer
15天前
已完结
Osimertinib after Chemoradiotherapy in Stage III EGFR -Mutated NSCLC
22天前
已完结
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study
22天前
已完结
Improving Dose-Optimization Processes Used in Oncology Drug Development to Minimize Toxicity and Maximize Benefit to Patients
22天前
已完结
Inappropriate use of progression-free survival in cancer drug approvals
24天前
已完结
皖公网安备34019202002308
